logo

For the Inventor, By the Inventor

Heiligenseestrasse, Germany

Nils G Morgenthaler

This inventor holds 21 USPTO granted patents and 8 published patent applications and 14 EPO patents. Top assignees: B.r.a.h.m.s Gmbh, B.r.a.h.m.s Aktiengesellschaft, Adrenomed Ag. Active years: 2006-2020.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Nils G Morgenthaler. Retrieved from https://idiyas.com/inventor/nils-g-morgenthaler

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 21 

% Patents Active = 85.7

 

Average Co-Inventor Count = 4.4

ph-index = 5

Forward Citations = 65(Granted Patents)


Location History:

  • Heiligenseestrasse, DE (2015)
  • Berlin, DE (2006 - 2020)

Company Filing History:

goldMedal18 out of 78 
 
B.r.a.h.m.s Gmbh
 patents
silverMedal2 out of 21 
 
B.r.a.h.m.s Aktiengesellschaft
 patents
bronzeMedal1 out of 10 
 
Adrenomed Ag
 patents

Years Active: 2006-2020

Loading Chart...
Loading Chart...
21 patents (USPTO):Explore Patents
1. 10718783 - Diagnosis and risk stratification of infections and chronic diseases of the respiratory tract and lungs by means of provasopressin, particularly copeptin or neurophysin II (2020-07-21),
2. 10254289 - In vitro method for early or differential diagnosis or prognosis of myocardial infarction in a patient (2019-04-09),
3. 10067063 - Prognosis and risk assessment in stroke patients by determining the level of marker peptides (2018-09-04),
4. 9829494 - Methods of treatment using ADM antibodies (2017-11-28),
5. 9513301 - Method for risk stratification in stable coronary artery disease (2016-12-06),
6. 9261517 - Diagnosis of acute coronary syndrome, myocardial infarction, or angina pectoris by means of neurophysin II (2016-02-16),
7. 9217742 - Method for risk stratification in stable coronary artery disease (2015-12-22),
8. 9040670 - Monoclonal thyroid stimulating or blocking antibodies, peptide sequences corresponding to their variable regions, and their uses in diagnostic, preventive and therapeutic medicine (2015-05-26),
9. 9012151 - Methods of diagnosis and risk stratification of adverse events in post myocardial infarction patients using pro-adrenomedullin (2015-04-21),
10. 8906857 - Methods for the diagnosis and treatment of critically ill patients with endothelin, endothelin agonists and adrenomedullin antagonists (2014-12-09),
11. 8735079 - Method for risk stratification in stable coronary artery disease (2014-05-27),
12. 8647830 - Method for determining amino-terminal proANP in patients having a cardiac disease or being suspected of developing or having a cardiac disease (2014-02-11),
13. 8524463 - Diagnosis and risk classification of acute coronary syndrome by means of CT-proET-1 in combination with NT-proBNP (2013-09-03),
14. 8501485 - Risk stratification for acute coronary syndrome by determining copeptin (2013-08-06),
15. 8465941 - Procalcitonin-based diagnosis of infections or inflammatory diseases of the respiratory tract in a patient with heart failure (2013-06-18),

Title: The Innovative Mind of Nils G Morgenthaler

Introduction

Nils G Morgenthaler, a prominent figure in the field of medical diagnostics, resides in Heiligenseestrasse, Germany. With an impressive portfolio of 21 patents, he has significantly contributed to advancing methods for diagnosing infections and chronic diseases, particularly concerning the respiratory tract and cardiovascular health.

Latest Patents

Among his notable recent patents, Morgenthaler developed innovative methodologies for risk stratification and diagnostics. One of these patents focuses on the diagnosis and risk stratification of infections and chronic diseases of the respiratory tract and lungs through the use of provasopressin, particularly copeptin or neurophysin II. This pioneering method aids in determining the presence of lower respiratory tract infections and chronic obstructive pulmonary disease, offering a robust diagnostic tool through the assessment of suitable biomarker combinations.

Additionally, he has invented an in vitro method for the early or differential diagnosis and prognosis of myocardial infarction in patients. This invention specifically addresses risk stratification for acute coronary syndrome, allowing for the detection of provasopressin to aid in diagnosing acute myocardial infarction and angina pectoris through innovative laboratory techniques.

Career Highlights

Morgenthaler has held significant roles in several reputable companies, most notably B.R.A.H.M.S GmbH and B.R.A.H.M.S Aktiengesellschaft. His work at these institutions has been foundational in driving forward the understanding and application of diagnostic methodologies in the clinical setting.

Collaborations

Throughout his career, Nils G Morgenthaler has collaborated with notable colleagues, including Andreas Bergmann and Joachim Struck. These collaborations have further enhanced the impact of his research and developments in the diagnostic field.

Conclusion

Nils G Morgenthaler's contributions to the field of medical diagnostics through his 21 patents reflect his dedication to improving healthcare outcomes. His innovative methods for diagnosing and stratifying risks associated with respiratory and cardiovascular diseases demonstrate the profound impact that determined inventors can have in advancing medical science.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…